Skip to main content
SpringerLink
Log in

Atrial fibrillation and stroke prevention: is warfarin still an option?—No

  • Neurology and Preclinical Neurological Studies - CONy Pro/Con debate
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Atrial fibrillation is a common arrhythmia that increases the risk of stroke by 4.5 times. Anticoagulant/antithrombotic therapy in atrial fibrillation has been inconsistent and inappropriate. Warfarin enjoyed the monopoly of being the primary medication used to reduce the risk of thromboembolic events. Warfarin has many limitations in its use as an ideal anticoagulant. To overcome this difficulty, now there are two main alternative groups to warfarin namely, direct thrombin inhibitors (ximelagatran and dabigatran) and factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, etc.). The advantages of the newer anticoagulants over the conventional warfarin are numerous. There are three landmark trials which have shown some light to the path of newer anticoagulant era, which include the following: RE-LY, ROCKET AF and ARISTOTLE. Head to head comparison of warfarin with newer anticoagulants showed the superiority of newer anticoagulants over warfarin in terms of efficacy and favorable side effect profile. After few decades of using warfarin, it‘s high time to enter into the era of newer anticoagulants and bid adieu to warfarin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • (2012) RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed RE-LY trial. ClinicalTrials.gov NCT00808067 (to be published)

  • Bousser MG, Bouthier J, Büller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Thorp-Pedersen C, Wyse DG (2008) Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371:315–321

    Article  PubMed  CAS  Google Scholar 

  • Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419–1426

    Article  PubMed  CAS  Google Scholar 

  • Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157:805–810

    Article  PubMed  CAS  Google Scholar 

  • Ferro D, Loffredo L, Polimeni L et al (2007) Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2:24–28

    Article  PubMed  CAS  Google Scholar 

  • Lopes RD, Alexander JH, Al-Khatib SM et al (2010) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159:331–339

    Article  PubMed  CAS  Google Scholar 

  • Olsson SB; Executive Steering Committee of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 362:1691–1698

    Article  Google Scholar 

  • Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891

    Article  PubMed  CAS  Google Scholar 

  • Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635–641

    Article  PubMed  CAS  Google Scholar 

  • Stafford RS, Singer DE (1998) Recent national patterns of warfarin use in atrial fibrillation. Circulation 97(13):1231–1233

    Article  PubMed  CAS  Google Scholar 

  • Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Neurology, Chennai, India

    R. Lakshmi Narasimhan Ranganathan & P. Venkatesh

Authors
  1. R. Lakshmi Narasimhan Ranganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Venkatesh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Lakshmi Narasimhan Ranganathan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranganathan, R.L.N., Venkatesh, P. Atrial fibrillation and stroke prevention: is warfarin still an option?—No. J Neural Transm 120, 1453–1456 (2013). https://doi.org/10.1007/s00702-012-0943-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-012-0943-3

Keywords

Search

Navigation